Published in Hepatitis Weekly, June 10th, 1996
A number of nucleosides have been found to inhibit hepatitis B virus (HBV) replication in vitro. Recently lamivudine (3TC) was shown to be effective in chronic hepatitis B in a double-blind, randomized clinical study. After three months of treatment at a dosage of 100 mg/kg/day, all patients exhibited undetectable serum levels of HBV DNA. Serum HBV DNA reappeared...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.